105 related articles for article (PubMed ID: 9873686)
1. Pyrimidinylimidazole inhibitors of CSBP/p38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes.
Adams JL; Boehm JC; Kassis S; Gorycki PD; Webb EF; Hall R; Sorenson M; Lee JC; Ayrton A; Griswold DE; Gallagher TF
Bioorg Med Chem Lett; 1998 Nov; 8(22):3111-6. PubMed ID: 9873686
[TBL] [Abstract][Full Text] [Related]
2. Pyrimidinylimidazole inhibitors of p38: cyclic N-1 imidazole substituents enhance p38 kinase inhibition and oral activity.
Adams JL; Boehm JC; Gallagher TF; Kassis S; Webb EF; Hall R; Sorenson M; Garigipati R; Griswold DE; Lee JC
Bioorg Med Chem Lett; 2001 Nov; 11(21):2867-70. PubMed ID: 11597418
[TBL] [Abstract][Full Text] [Related]
3. Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes.
Laufer SA; Wagner GK; Kotschenreuther DA; Albrecht W
J Med Chem; 2003 Jul; 46(15):3230-44. PubMed ID: 12852754
[TBL] [Abstract][Full Text] [Related]
4. Imidazopyrimidines, potent inhibitors of p38 MAP kinase.
Rupert KC; Henry JR; Dodd JH; Wadsworth SA; Cavender DE; Olini GC; Fahmy B; Siekierka JJ
Bioorg Med Chem Lett; 2003 Feb; 13(3):347-50. PubMed ID: 12565927
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase.
Liverton NJ; Butcher JW; Claiborne CF; Claremon DA; Libby BE; Nguyen KT; Pitzenberger SM; Selnick HG; Smith GR; Tebben A; Vacca JP; Varga SL; Agarwal L; Dancheck K; Forsyth AJ; Fletcher DS; Frantz B; Hanlon WA; Harper CF; Hofsess SJ; Kostura M; Lin J; Luell S; O'Neill EA; O'Keefe SJ
J Med Chem; 1999 Jun; 42(12):2180-90. PubMed ID: 10377223
[TBL] [Abstract][Full Text] [Related]
6. A single amino acid substitution makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinase.
Fox T; Coll JT; Xie X; Ford PJ; Germann UA; Porter MD; Pazhanisamy S; Fleming MA; Galullo V; Su MS; Wilson KP
Protein Sci; 1998 Nov; 7(11):2249-55. PubMed ID: 9827991
[TBL] [Abstract][Full Text] [Related]
7. Regulation of stress-induced cytokine production by pyridinylimidazoles; inhibition of CSBP kinase.
Gallagher TF; Seibel GL; Kassis S; Laydon JT; Blumenthal MJ; Lee JC; Lee D; Boehm JC; Fier-Thompson SM; Abt JW; Soreson ME; Smietana JM; Hall RF; Garigipati RS; Bender PE; Erhard KF; Krog AJ; Hofmann GA; Sheldrake PL; McDonnell PC; Kumar S; Young PR; Adams JL
Bioorg Med Chem; 1997 Jan; 5(1):49-64. PubMed ID: 9043657
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological effects of SB 220025, a selective inhibitor of P38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models.
Jackson JR; Bolognese B; Hillegass L; Kassis S; Adams J; Griswold DE; Winkler JD
J Pharmacol Exp Ther; 1998 Feb; 284(2):687-92. PubMed ID: 9454815
[TBL] [Abstract][Full Text] [Related]
9. Novel homologues of CSBP/p38 MAP kinase: activation, substrate specificity and sensitivity to inhibition by pyridinyl imidazoles.
Kumar S; McDonnell PC; Gum RJ; Hand AT; Lee JC; Young PR
Biochem Biophys Res Commun; 1997 Jun; 235(3):533-8. PubMed ID: 9207191
[TBL] [Abstract][Full Text] [Related]
10. SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence.
Underwood DC; Osborn RR; Kotzer CJ; Adams JL; Lee JC; Webb EF; Carpenter DC; Bochnowicz S; Thomas HC; Hay DW; Griswold DE
J Pharmacol Exp Ther; 2000 Apr; 293(1):281-8. PubMed ID: 10734180
[TBL] [Abstract][Full Text] [Related]
11. An algorithm-directed two-component library synthesized via solid-phase methodology yielding potent and orally bioavailable p38 MAP kinase inhibitors.
McKenna JM; Halley F; Souness JE; McLay IM; Pickett SD; Collis AJ; Page K; Ahmed I
J Med Chem; 2002 May; 45(11):2173-84. PubMed ID: 12014955
[TBL] [Abstract][Full Text] [Related]
12. Potent inhibitors of the MAP kinase p38.
Henry JR; Rupert KC; Dodd JH; Turchi IJ; Wadsworth SA; Cavender DE; Schafer PH; Siekierka JJ
Bioorg Med Chem Lett; 1998 Dec; 8(23):3335-40. PubMed ID: 9873730
[TBL] [Abstract][Full Text] [Related]
13. Phenoxypyrimidine inhibitors of p38alpha kinase: synthesis and statistical evaluation of the p38 inhibitory potencies of a series of 1-(piperidin-4-yl)-4-(4-fluorophenyl)-5-(2-phenoxypyrimidin-4-yl) imidazoles.
Boehm JC; Bower MJ; Gallagher TF; Kassis S; Johnson SR; Adams JL
Bioorg Med Chem Lett; 2001 May; 11(9):1123-6. PubMed ID: 11354358
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of ML3403 ({4-[5-(4-fluorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-(1-phenylethyl)-amine), a 4-Pyridinylimidazole-type p38 mitogen-activated protein kinase inhibitor.
Kammerer B; Scheible H; Albrecht W; Gleiter CH; Laufer S
Drug Metab Dispos; 2007 Jun; 35(6):875-83. PubMed ID: 17344341
[TBL] [Abstract][Full Text] [Related]
15. From imidazoles to pyrimidines: new inhibitors of cytokine release.
Laufer SA; Wagner GK
J Med Chem; 2002 Jun; 45(13):2733-40. PubMed ID: 12061876
[TBL] [Abstract][Full Text] [Related]
16. Arachidonic acid directly activates members of the mitogen-activated protein kinase superfamily in rabbit proximal tubule cells.
Alexander LD; Cui XL; Falck JR; Douglas JG
Kidney Int; 2001 Jun; 59(6):2039-53. PubMed ID: 11380805
[TBL] [Abstract][Full Text] [Related]
17. Potent, orally absorbed glucagon receptor antagonists.
de Laszlo SE; Hacker C; Li B; Kim D; MacCoss M; Mantlo N; Pivnichny JV; Colwell L; Koch GE; Cascieri MA; Hagmann WK
Bioorg Med Chem Lett; 1999 Mar; 9(5):641-6. PubMed ID: 10201821
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors of p38 mitogen-activated protein kinase promote neuronal survival in vitro.
Horstmann S; Kahle PJ; Borasio GD
J Neurosci Res; 1998 May; 52(4):483-90. PubMed ID: 9589393
[TBL] [Abstract][Full Text] [Related]
19. P38 MAP kinase inhibitors: evolution of imidazole-based and pyrido-pyrimidin-2-one lead classes.
Natarajan SR; Doherty JB
Curr Top Med Chem; 2005; 5(10):987-1003. PubMed ID: 16178742
[TBL] [Abstract][Full Text] [Related]
20. SAR of 4-hydroxypiperidine and hydroxyalkyl substituted heterocycles as novel p38 map kinase inhibitors.
Revesz L; Di Padova FE; Buhl T; Feifel R; Gram H; Hiestand P; Manning U; Zimmerlin AG
Bioorg Med Chem Lett; 2000 Jun; 10(11):1261-4. PubMed ID: 10866395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
